The use of transdermal fentanyl in the treatment of cancer pain

Archive of Oncology

Volumn 10, Issue 4, 2002, Pages 263-266

  Radovanović, Dragana ^a   Pjević, Miroslava ^b   Malbaša, Zlatica ^a   Stokić, Aleksandar ^a  

^a Institute of Oncology Sremska Kamenica   (Yugoslavia)

^b Clinical Center Novi Sad   (Yugoslavia)

Author keywords

Administration Cutaneus; Analgesics, Opioid; Fentanyl; Neoplasms; Pain

Indexed keywords

ALCOHOL; ANESTHETIC AGENT; ANTIHISTAMINIC AGENT; CARBAMAZEPINE; CENTRAL DEPRESSANT AGENT; CODEINE; CYTOCHROME P450 3A4; FENTANYL; HYDROMORPHONE; HYPNOTIC AGENT; MACROLIDE; METHADONE; MORPHINE; MUSCLE RELAXANT AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; OXYCODONE; OXYMORPHONE; PARACETAMOL; PHENOTHIAZINE DERIVATIVE; PHENYTOIN; PROTEINASE INHIBITOR; PYRROLE DERIVATIVE; SEDATIVE AGENT;

ARTICLE; CANCER PAIN; CANCER PALLIATIVE THERAPY; CLINICAL TRIAL; CONSTIPATION; DRUG CHOICE; DRUG CONTRAINDICATION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SAFETY; DRUG USE; EDEMA; ERYTHEMA; HUMAN; HYPOTENSION; HYPOVENTILATION; MYOCLONUS; NAUSEA; PAIN ASSESSMENT; PAPULE; PATIENT ATTITUDE; PRURITUS; RESPIRATION DEPRESSION; SEDATION; SIDE EFFECT; SKIN SENSITIVITY; VOMITING;

EID: 0036978523     PISSN: 03547310     EISSN: None     Source Type: Journal    
DOI: 10.2298/AOO0204263R     Document Type: Article

References (19)

1. World Health Organization. Cancer pain relief. 2nd ed. Geneva: WHO, 1996: 17.
2. Hanks GW, de Conno F, Cherny N, et al. Morphine and alternative opioids in cancer pain: the EAPC recommendations. Br J Cancer 2001; 84(5):587-93.
3. Muijsers RBR, Wagstaff AJ. Transdermal fentanyl: An updated review of its pharmacological properties and therapeutic efficacy in chronic cancer pain control. Drugs 2001; 61(15):2289-307.
4. Radbruch L, Sabatowski R, Petzke F, Brunsch-Radbruch A, Grond S, Lehmann KA. Transdermal fentanyl for the management of cancer pain: a survey of 1005 patients. Palliat Med 2001; 15(4):309-21.
5. Gourlay GK. Treatment of cancer pain with transdermal fentanyl. Lancet Oncol 2001; 2(3):165-72.
6. Mystakidou K, Befon S, Kouskouni E, Gerolymatos K, Georgaki S, Tsilika E, Vlahos L. From codeine to transdermal fentanyl for cancer pain control: a safety and efficacy clinical trial. Anticancer Res 2001; 21(3C):2225-30.
7. Vielvoye-Kerkmeer AP, Mattern C, Uitendaal MP. Transdermal fentanyl in opioid-naive cancer pain patients: an open trial using transdermal fentanyl for the treatment of chronic cancer pain in opioid-naive patients and a group using codeine. J Pain Symptom Manage 2000; 19(3):185-92.
8. Donner B, Zenz M, Strumpf M, Raber M. Long-term treatment of cancer pain with transdermal fentanyl. J Pain Symptom Manage 1998; 15(3):168-75.
9. Murphy M, Carmichael AJ. Transdermal drug delivery systems and skin sensitivity reactions. Incidence and management. Am J Clin Dermatol 2000; 1(6):361-8.
10. Payne R. Factors influencing quality of life in cancer patients: the role of transdermal fentanyl in the management of pain. Semin Oncol 1998; 25(3 Suppl 7):47-53.
11. Varvel JR, Shafer SL, Hwang SS, et al. Absorption characteristics of transdermally administered fentanyl. Anesthesiology 1989; 70:928-34.
12. Janssen Pharmaceutica. Durogesic (Fentanyl transdermal system) full prescribing information (US). 2001.
13. Jeal W, Benfield P. Transdermal fentanyl: a review of its pharmacological properties and therapeutic efficacy in pain control. Drugs 1997; 53(1):109-38.
14. Breitbart W, Chandler S, Eagel B, Ellison N, Enck RE, Lefkowitz M, Payne R. An alternative algorithm for dosing transdermal fentanyl for cancer-related pain. Oncology (Huntingt) 2000; 14(5):695-705.
15. Klockgether-Radke AP, Gaus P, Neumann P. Opioid intoxication following transdermal administration of fentanyl. Anaesthesist 2002; 51 (4):269-71.
16. Nugent M, Davis C, Brooks D, Ahmedzai SH. Long-term observations of patients receiving transdermal fentanyl after a randomized trial. J Pain Symptom Manage 2001; 21(5):385-91.
17. Kongsgaard UE, Poulain P. Transdermal fentanyl for pain control in adults with chronic cancer pain. Eur J Pain 1998; 2(1):53-62.
18. Radbruch L, Sabatowski R, Loick G, Kulbe C, Kasper M, Grond S, Lehmann KA. Constipation and the use of laxatives: a comparison between transdermal fentanyl and oral morphine. Palliat Med 2000; 14(2):111-9.
19. Iconomou G, Viha A, Vagenakis AG, Kalofonos HP. Transdermal fentanyl in cancer patients with moderate-to-severe pain: a prospective examination. Anticancer Res 2000; 20(6C):4821-4.